Zoloft and Parathyroid tumor benign - a phase IV clinical study of FDA data

Summary:

Parathyroid tumor benign is reported as a side effect among people who take Zoloft (sertraline hydrochloride), especially for people who are female, 60+ old, also take Aredia, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Parathyroid tumor benign when taking Zoloft. It is created by eHealthMe based on reports of 128,159 people who have side effects when taking Zoloft from the FDA, and is updated regularly.

What is Zoloft?

Zoloft has active ingredients of sertraline hydrochloride. It is often used in depression. eHealthMe is studying from 138,801 Zoloft users. Check the latest studies of Zoloft.

What is Parathyroid tumor benign?

Parathyroid tumor benign is found to be associated with 163 drugs and 231 conditions by eHealthMe. Check the latest studies of Parathyroid tumor benign.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

128,159 people reported to have side effects when taking Zoloft.
Among them, 29 people (0.02%) have Parathyroid tumor benign.

Could Zoloft cause Parathyroid tumor benign?

Among these 29 people:

What is the gender of people who have Parathyroid tumor benign when taking Zoloft? *

female: 53.57 %
male: 46.43 %

What is the age of people who have Parathyroid tumor benign when taking Zoloft? *

What are other drugs people take besides Zoloft? *

What are other side effects people have besides Parathyroid tumor benign? *

Pain: 26 people, 89.66%
Infection: 24 people, 82.76%
Nausea (feeling of having an urge to vomit): 23 people, 79.31%
Headache (pain in head): 23 people, 79.31%
Dizziness: 21 people, 72.41%
Pain In Extremity: 19 people, 65.52%
Osteonecrosis Of Jaw (death of bone of jaw): 19 people, 65.52%
Spinal Osteoarthritis (joint cartilage loss in spine): 19 people, 65.52%
Constipation: 19 people, 65.52%
Abdominal Pain: 18 people, 62.07%

What are the existing conditions these people have? *

High Blood Cholesterol: 12 people, 41.38%
Prostate Cancer: 11 people, 37.93%
Osteoporosis (bones weak and more likely to break): 11 people, 37.93%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 5 people, 17.24%
Multiple Myeloma (cancer of the plasma cells): 3 people, 10.34%
High Blood Pressure: 2 people, 6.90%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.90%
Weight Loss: 1 person, 3.45%
Urination - Excessive Volume: 1 person, 3.45%
Pain: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Zoloft and have Parathyroid tumor benign?

- Check whether Parathyroid tumor benign is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoloft:

Zoloft (138,801 reports)

Browse all side effects of Zoloft:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Parathyroid tumor benign:

Parathyroid tumor benign (163 drugs)

Browse all the conditions that are associated with Parathyroid tumor benign:

Parathyroid tumor benign (231 conditions)

Related publications that referenced our studies

Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .
Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on sertraline hydrochloride (the active ingredients of Zoloft) and Zoloft (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.